Search research articles
Contact Us
Filters
Showing results (21-30 of 24) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 24 results.
Theranostics
|
February 16, 2026
A cochlea-sparing strategy for non-invasive control of intracranial schwannomas via peripheral irradiation and anti-PD-1 therapy enhanced by STING activation
Zhenzhen Yin, Simeng Lu, Limeng Wu, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
February 27, 2026
Deciphering and Targeting the Schwannoma-Neuron-Macrophage Crosstalk for the Treatment of Schwannomatosis and Associated Pain
Zhenzhen Yin, Limeng Wu, Yanling Zhang, et al.
Biorxiv : the Preprint Server for Biology
|
January 7, 2025
Enhanced Tumor Control and Hearing Loss Prevention Achieved with Combined Immune Checkpoint Inhibitor and Anti-VEGF Therapy in Vestibular Schwannoma Model
Simeng Lu, Zhenzhen Yin, Limeng Wu, et al.
Nature Communications
|
February 11, 2026
NKG2D upregulation sensitizes tumors to combined anti-PD1 and anti-VEGF therapy and prevents hearing loss
Simeng Lu, Zhenzhen Yin, Limeng Wu, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 24) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 24 results.
Theranostics
|
February 16, 2026
A cochlea-sparing strategy for non-invasive control of intracranial schwannomas via peripheral irradiation and anti-PD-1 therapy enhanced by STING activation
Zhenzhen Yin, Simeng Lu, Limeng Wu, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
February 27, 2026
Deciphering and Targeting the Schwannoma-Neuron-Macrophage Crosstalk for the Treatment of Schwannomatosis and Associated Pain
Zhenzhen Yin, Limeng Wu, Yanling Zhang, et al.
Biorxiv : the Preprint Server for Biology
|
January 7, 2025
Enhanced Tumor Control and Hearing Loss Prevention Achieved with Combined Immune Checkpoint Inhibitor and Anti-VEGF Therapy in Vestibular Schwannoma Model
Simeng Lu, Zhenzhen Yin, Limeng Wu, et al.
Nature Communications
|
February 11, 2026
NKG2D upregulation sensitizes tumors to combined anti-PD1 and anti-VEGF therapy and prevents hearing loss
Simeng Lu, Zhenzhen Yin, Limeng Wu, et al.
Page
of 3